Saturday, December, 15, 2018 12:25:55

Contribution By Sunil Hebbalkar


Microsoft purchases app-provisioning platform provider FSLogix

Technology conglomerate Microsoft reportedly announced to have purchased the Georgia-based startup FSLogix, which is predominantly known for its FSLogix app provisioning platform. As per trusted sources, the technology of FSLogix will speed up load times for user profiles in Microsoft’s OneDrive and Outlook, improving the …

Microsoft buys Xoxco as it looks to boost AI and bot development

Microsoft has announced that is has acquired Xoxco, an Austin-based software startup which focuses on bot development and conversational artificial intelligence. The value of the deal was not disclosed by the companies, but sources close to the matter commented the acquisition aligns well with Microsoft’s …

Cisco to offer enhanced integrated SD-WAN security & cloud services

Globally renowned network hardware provider, Cisco Systems, Inc., in a bid to offer its customers enhanced IT service, plans to integrate its SD-WAN (software-defined wide-area networking) software with security features while improving support for cloud services. As per Ramesh Prabagaran, Cisco’s Senior Director of Product …

Expert System and Rabobank to collaborate on cognitive AI platform

The artificial intelligence firm Expert System and Rabobank, a financial services company have reportedly entered into a partnership for leveraging the power of Expert Systems flagship platform, Cogito®. The platform is based on a unique blend of Artificial Intelligence (AI) technology and machine learning. Apparently, …

Amazon launches Audible in India, service still in beta stage

Recently Amazon announced the launching of its audiobook service Audible in India. The subscription-based service that has been much awaited in the country is the second to be launched by the online retail behemoth after it launched Prime. The Audible subscription is expected to complement …

U.S. FDA approves Pfizer Inc’s lung cancer medicine LORBRENA®

Pfizer Inc., the New York-based pharmaceutical company, has reportedly announced that its third-generation lung cancer drug LORBRENA has been approved by the U.S. Food & Drug Administration (FDA). Reports cite, the drug – an ALK TKI (Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor) – is designed …